Table 2 Correlation of Circ-SMARCA5 relative expression with patients’ characteristics
From: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
Characteristics | Circ-SMARCA5 relative expression | p value | |
|---|---|---|---|
High | Low | ||
Age (n/%) | 0.143 | ||
< 60 years | 23 (43.4) | 30 (56.6) | |
≥ 60 years | 30 (57.7) | 22 (42.3) | |
Gender (n/%) | 0.632 | ||
Male | 34 (52.3) | 31 (47.7) | |
Female | 19 (47.5) | 21 (52.5) | |
Immunoglobulin subtypes (n/%) | 0.537 | ||
IgA | 14 (58.3) | 10 (41.7) | |
IgG | 31 (52.5) | 28 (47.5) | |
IgD | 1 (50.0) | 1 (50.0) | |
Bence-Jones protein | 7 (36.8) | 12 (63.2) | |
IgM | 0 (0.0) | 1 (100.0) | |
Hb (n/%) | 0.494 | ||
< 10 g/dL | 28 (53.8) | 24 (46.2) | |
≥ 10 g/dL | 25 (47.12) | 28 (52.8) | |
Calcium (n/%) | 0.346 | ||
< 11.5 mg/dL | 41 (53.2) | 36 (46.8) | |
≥ 11.5 mg/dL | 12 (42.9) | 16 (57.1) | |
Scr (n/%) | 0.604 | ||
< 2 mg/dL | 42 (51.9) | 39 (48.1) | |
≥ 2 mg/dL | 11 (45.8) | 13 (54.2) | |
ALB (n/%) | 0.782 | ||
< 3.5 mg/dL | 16 (48.5) | 17 (51.5) | |
≥ 3.5 mg/dL | 37 (51.4) | 35 (48.6) | |
β2-MG (n/%) | 0.001 | ||
< 5.5 mg/L | 39 (65.0) | 21 (35.0) | |
≥ 5.5 mg/L | 14 (31.3) | 31 (68.9) | |
LDH (n/%) | 0.361 | ||
< 220 U/L | 39 (53.4) | 34 (46.6) | |
≥ 220 U/L | 14 (43.8) | 18 (56.3) | |
Durie-Salmon stage (n/%) | 0.650 | ||
I | 3 (75.0) | 1 (25.0) | |
II | 22 (44.9) | 27 (55.1) | |
III | 28 (53.8) | 24 (46.2) | |
ISS stage (n/%) | < 0.001 | ||
I | 18 (75.0) | 6 (25.0) | |
II | 21 (58.3) | 15 (41.7) | |
III | 14 (31.1) | 31 (68.9) | |
Bone lesion (n/%) | 0.174 | ||
Yes | 41 (54.7) | 34 (45.3) | |
No | 12 (40.0) | 18 (60.0) | |
Cytogenetics abnormalities (n/%) | |||
t (14; 16) translocation | 0.056 | ||
Yes | 11 (73.3) | 4 (26.7) | |
No | 42 (46.7) | 48 (53.3) | |
t (4; 14) translocation | 0.486 | ||
Yes | 4 (40.0) | 6 (60.0) | |
No | 49 (51.6) | 46 (48.4) | |
Del (17p) | 0.235 | ||
Yes | 5 (35.7) | 9 (64.3) | |
No | 48 (52.7) | 43 (47.3) | |